BioCryst (BCRX) director receives stock units and options grants

Rhea-AI Filing Summary

BioCryst Pharmaceuticals director Jon P. Stonehouse reported routine equity compensation grants. He received 15,294 shares of Common Stock as a grant, increasing his direct holdings to 1,339,775 shares. These shares were granted at no cash cost as part of his non-employee director compensation.

He was also granted an Automatic Stock Option for 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. Footnotes explain these are automatic non-employee director grants of Restricted Stock Units and stock options under BioCryst’s Director Compensation Policy. Two family irrevocable trusts associated with his wife each report indirect holdings of 40,000 Common Stock shares.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Stonehouse Jon P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	--
Grant/Award	Common Stock	15,294	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Automatic Stock Option Grant — 33,540 shares (Direct, null); Common Stock — 1,339,775 shares (Direct, null); Common Stock — 40,000 shares (Indirect, By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust)

Footnotes (1)

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

RSU grant: 15,294 shares Direct holdings after grant: 1,339,775 shares Stock option grant size: 33,540 options +4 more

7 metrics

RSU grant 15,294 shares Automatic non-employee director grant of Restricted Stock Units

Direct holdings after grant 1,339,775 shares Common Stock directly held after RSU grant

Stock option grant size 33,540 options Automatic Stock Option Grant for Common Stock

Option exercise price $8.50 per share Exercise price for Automatic Stock Option Grant

Option expiration June 11, 2036 Expiration date of Automatic Stock Option Grant

Indirect trust holding (Samuel trust) 40,000 shares Common Stock held by Samuel Stonehouse Irrevocable Trust

Indirect trust holding (Caroline trust) 40,000 shares Common Stock held by Caroline Stonehouse Irrevocable Trust

Key Terms

Restricted Stock Units, Director Compensation Policy, Automatic Stock Option Grant, Irrevocable Trust

4 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Director Compensation Policy financial

"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy")"

Automatic Stock Option Grant financial

"security_title": "Automatic Stock Option Grant""

Irrevocable Trust financial

"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stonehouse Jon P

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	1,339,775	D
Common Stock								40,000	I	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
Common Stock								40,000	I	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(2)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did BioCryst (BCRX) report for Jon P. Stonehouse?

BioCryst reported that director Jon P. Stonehouse received equity compensation grants. He was awarded 15,294 shares of Common Stock and an Automatic Stock Option for 33,540 shares, all under the company’s non-employee Director Compensation Policy.

How many BioCryst (BCRX) shares did Jon P. Stonehouse directly hold after this Form 4?

After the reported grants, Jon P. Stonehouse directly held 1,339,775 shares of BioCryst Common Stock. This total reflects the addition of 15,294 granted shares, which were issued at no cash cost as part of his director compensation.

What are the terms of Jon P. Stonehouse’s new stock options in BioCryst (BCRX)?

Stonehouse received an Automatic Stock Option covering 33,540 shares of BioCryst Common Stock at an exercise price of $8.50 per share. The option expires on June 11, 2036 and was granted under the company’s Director Compensation Policy.

How do the Restricted Stock Units granted to Jon P. Stonehouse in BioCryst (BCRX) vest?

The 15,294 Restricted Stock Units granted to Stonehouse will vest on the first anniversary of the grant date. This vesting schedule is set by BioCryst’s Non-Employee Director Compensation Policy, which governs automatic equity awards to non-employee directors.

What indirect BioCryst (BCRX) holdings related to Jon P. Stonehouse were reported?

The filing shows two indirect positions, each listing 40,000 Common Stock shares held by irrevocable trusts named for Samuel and Caroline Stonehouse. His wife is reported as co-trustee of both trusts, and these holdings are reported as indirect ownership.